# Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

> **NCT05891821** · PHASE2 · RECRUITING · sponsor: **Immune Oncology Research Institute** · enrollment: 20 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Balstilimab

## Key facts

- **NCT ID:** NCT05891821
- **Lead sponsor:** Immune Oncology Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891821, "Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05891821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*